<DOC>
	<DOCNO>NCT01023607</DOCNO>
	<brief_summary>Many trial suggest lipid lowering therapy could significantly reduce cardiovascular event . Enhancing stability vulnerable plaque probably main reason statin reduce adverse coronary event . The size lipid core fibrous cap thickness ( FCT ) major determinant plaque vulnerability . So , important accurately evaluate change plaque stain therapy . Previous report suggest intensive lipid lower therapy provide significantly clinical benefit compare moderate lipid lower therapy.Such benefit may contribute change follow parameter : FCT , lipid arc ( quadrant ) , TCFA , macrophage , plaque disruption , thrombus measure OCT , plaque burden remodel index IVUS . Current intravascular imaging modality , optical coherence tomography ( OCT ) intravascular ultrasound ( IVUS ) provide vivo quantitative qualitative information coronary plaque . However , study aim monitor progression coronary plaque patient receive statin therapy OCT combine IVUS . Therefore , study design compare effect rosuvastatin 10mg , atorvastatin 20mg atorvastatin 60mg treatment change FCT lipid core arc OCT plaque burden IVUS coronary atherosclerotic plaque .</brief_summary>
	<brief_title>Evaluation Statin-induced Lipid-rich Plaque Progression Optical Coherence Tomography ( OCT ) Combined With Intravascular Ultrasound ( IVUS )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Age :1875Y 2 . Clinical indication coronary angiography ( CAG ) . 3 . CAG demonstrate least 1 de novo lesion luminal diameter stenosis 20 % 70 % ( visual estimation ) . 4 . OCT demonstrate lesion lipidrich plaque ( FCT ≤200μm lipid arc ≥100o ) . 5 . LDLC range 70mg /dl 160mg /dl . 6 . Patient legal guardian understands agree comply specify study requirement provide write informed consent . Exclusion criterion : 1 . Life expectancy &lt; 12 month due another medical condition . 2 . Contraindication atorvastatin rosuvastatin . 3 . Creatinine level 2.0mg/dL ESRD . 4 . Severe hepatic dysfunction ( AST and/or ALT 3 time upper limit normal ) . 5 . Congestive heart failure ( left ventricle eject fraction ≤35 % ) . 6 . Female childbearing potential positive pregnancy test within 7 day study , lactate , intend become pregnant follow 12 month . 7 . The patient likely require coronary bypass surgery , cardiac transplantation , surgical repair replacement course . Exit criterion 1 . ALT/AST ≥ 3times upper limit normal enrollment . 2 . Muscle ache/myopathy . 3 . Lose followup . 4 . Patient insists exit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>optical coherence tomography</keyword>
	<keyword>intravascular ultrasound</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>